Abstract
Corporate finances influence many areas of science, originating with tobacco companies which hired public relations firms to protect their profits from research on the harms of smoking. Despite a large body of studies finding that money biases research, scientists and academic organizations fail to embrace the peer-reviewed research on corporate influence . In many instances, they reject the science and try to rationalize behavior, leading a cycle of scandal, followed by reform, followed by later scandal. Because corporate influence is so pervasive and often denied, policymakers must understand this history as well as the research on financial conflicts of interest to protect the public.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abel, D. (2016, March 19). How public must science be? Union of Concerned Scientists would limit disclosures. Boston Globe.
Academies, T. N. (2003). Conflicts of interest policy for committees used in the development of reports. Online.
Administrator. (2008). A comment from Paul Gelsinger on gene therapy and informed consent. Retrieved from http://www.bioethics.net/2008/01/a-comment-from-paul-gelsinger-on-gene-therapy-and/.
Ancker, J. S., & Flanagin, A. (2007). A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines. Science and Engineering Ethics, 13(2), 147–157. https://doi.org/10.1007/s11948-007-9011-z.
Anderson, C. (1994). Agencies set rules on financial disclosure. Science, 265(5169), 179–180.
Bekelman, J. E., Li, Y., & Gross, C. P. (2003). Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA, 289(4), 454–465.
Bero, L. A., & Rennie, D. (1996). Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care, 12(2), 209–237.
Blumenthal, D., Campbell, E. G., Anderson, M. S., Causino, N., & Louis, K. S. (1997). Withholding research results in academic life science. Evidence from a national survey of faculty. JAMA, 277(15), 1224–1228.
Boffey, P. (1975). The Brain Bank of America: An inquiry into the politics of science. New York, NY: McGraw-Hill.
Boyd, E. A., & Bero, L. A. (2000). Assessing faculty financial relationships with industry: A case study. JAMA, 284(17), 2209–2214.
Brandt, A. M. (2007). The cigarette century: The rise, fall, and deadly persistence of the product that defined America. New York, NY: Basic Books.
Brandt, A. M. (2012). Inventing conflicts of interest: A history of tobacco industry tactics. American Journal of Public Health, 102(1), 63–71. https://doi.org/10.2105/AJPH.2011.300292.
Brian, D. (2011). [Letter to FDA Commissioner, Margaret Hamburg, via Email].
Brownell, K. D., & Warner, K. E. (2009). The perils of ignoring history: Big tobacco played dirty and millions died. How similar is big food? Milbank Q, 87(1), 259–294. https://doi.org/10.1111/j.1468-0009.2009.00555.x.
Brownlee, S. (2015). The conflict denialists strike back. Retrieved from http://lowninstitute.org/news/the-conflict-denialists-strike-back/.
Burling, C. (1963). Public relations in the field of smoking and health. Industry Documents. Retrieved April 30, 2018 https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/htfl0012.
Cappola, A. R., & FitzGerald, G. A. (2015). Confluence, not conflict of interest: Name change necessary. JAMA, 314(17), 1791–1792. https://doi.org/10.1001/jama.2015.12020.
Carlat, D. (2007, November 25). Dr. Drug Rep. New York Times.
Cauchon, D. (2000, September 25). FDA advisers tied to industry. USA Today.
Centers, A. o. A. H. (1990). Conflicts of interest in academic health centers. Washington, DC.
Cho, M. K., & Bero, L. A. (1996). The quality of drug studies published in symposium proceedings. Annals of Internal Medicine, 124(5), 485–489.
Chren, M. M., & Landefeld, C. S. (1994). Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA, 271(9), 684–689.
Cohen, R. (2000, September 24, 2000). Conference call. New York Times Magazine.
Cohn, V. (1971, April 26). Science academy facing cries for reform. Washington Post.
Colleges, A. o. A. M. (1990). Guidelines for dealing with faculty conflicts of commitment and conflicts of interest in research. Ethics Codes Collection.
Committee, T. I. R. (1954). A frank statement to cigarette smokers. Industry Documents. Retrieved April 30, 2018, from https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/zkph0129.
Conflict of Interest in Medical Research, Education, and Practice. (2009). Retrieved from.
Cronin, J. (2017). PubMed to include conflict-of-interest statements with study abstracts [Press release]. Retrieved from https://cspinet.org/news/pubmed-include-conflict-interest-statements-study-abstracts-20170418.
Culliton, B. J. (1982). The academic-industrial complex. Science, 216(4549), 960–962.
Davis, C. (2014). Red tape tightrope: Regulating financial conflicts of interest in FDA advisory committees. Washington University Law Review, 91(6).
DeAngelis, C. D. (2000). Conflict of interest and the public trust. JAMA, 284(17), 2237–2238.
DeAngelis, C. D., & Fontanarosa, P. B. (2008). Impugning the integrity of medical science: The adverse effects of industry influence. JAMA, 299(15), 1833–1835. https://doi.org/10.1001/jama.299.15.1833.
Editors. (2014, May 31). Secrecy that kills. New York Times.
Elliott, C. (2006). The drug pushers. Atlantic Magazine.
Facher, L. (2018, April 19). NIH abruptly changes course on industry opioids partnership after ethics flags raised. STAT. Retrieved from https://www.statnews.com/2018/04/19/nih-industry-partnership-ethics-opioids/.
Fauber, J. (2014, June 25). 9 of 19 experts on pain panel tied to drug companies. Milwaukee Journal Sentinel.
Friedberg, M., Saffran, B., Stinson, T. J., Nelson, W., & Bennett, C. L. (1999). Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 282(15), 1453–1457.
Friedman, L. S., & Richter, E. D. (2004). Relationship between conflicts of interest and research results. Journal of General Internal Medicine, 19(1), 51–56.
Friedman, P. J. (2002). The impact of conflict of interest on trust in science. Science and Engineering Ethics, 8(3), 413–420.
Gibson, L. (2004). GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ, 328(7455), 1513. https://doi.org/10.1136/bmj.328.7455.1513-a.
Gillette, R. (1972). Academy food committees: New criticism of industry ties. Science, 177(4055), 1172–1175. https://doi.org/10.1126/science.177.4055.1172.
Gingras, Y., & Gosselin, P. M. (2008). The emergence and evolution of the expression “conflict of interests” in science: A historical overview, 1880–2006. Science and Engineering Ethics, 14(3), 337–343. https://doi.org/10.1007/s11948-008-9063-8.
Goldberg, D. S. (2015). COI bingo BMJ opinion. https://blogs.bmj.com/bmj/2015/08/24/daniel-s-goldberg-coi-bingo/.
Guttman, D. W. B. (1976). The shadow government: The government’s multi-billion-dollar giveaway of its decision-making powers to private management consultants, “experts,” and think tanks. New York, NY: Pantheon.
Hampson, L. A., Agrawal, M., Joffe, S., Gross, C. P., Verter, J., & Emanuel, E. J. (2006). Patients’ views on financial conflicts of interest in cancer research trials. New England Journal of Medicine, 355(22), 2330–2337. https://doi.org/10.1056/NEJMsa064160.
Hanmer, H. (1954). Re: Rewrite of “White Paper” introduction. Industry Documents. Retrieved April 30, 2018, from Ness Motley Law Firm Documents. https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/ltyc0040.
Healy, D. (2006). Did regulators fail over selective serotonin reuptake inhibitors? BMJ, 333(7558), 92–95. https://doi.org/10.1136/bmj.333.7558.92.
Healy, D., & Cattell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 183, 22–27.
Hill, J. (1962). Smoking, health and statistics: The story of the tobacco accounts. Industry Documents. Retrieved April 30, 2018, from Hill & Knowlton Inc. https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/tyfl0060.
Inc, H. K. (1953). Preliminary recommendations for cigarette manufacturers. Industry Documents. Retrieved April 30, 2018, from Unknown. https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/rsfy0137.
Inc, H. K. (1954). Press release, re: Timothy V. Hartnett named as full-time chairman of Tobacco Industry Research Committee. Retrieved from Hill & Knowlton Inc. https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/jxwb0035.
Inc, H. K. (1958). Ex-Congressman Richards to Head Newly-Formed Tobacco Institute, Inc.
Institutional Financial Conflicts of Interest in Research Universities, Symposium Report. (2012). Retrieved from Cambridge, MA. http://petrieflom.law.harvard.edu/assets/publications/fCOI_final_report.pdf.
Jasanoff, S. (1998). The fifth branch: Science advisors as policy makers. Boston, MA: Harvard University Press.
Jukes, T. H. (1983). Philip Handler (1917–1981). A biographical sketch. The Journal of Nutrition, 113(6), 1086–1094.
Kaiser, J. (2005). Conflict of interest. NIH chief clamps down on consulting and stock ownership. Science, 307(5711), 824–825. https://doi.org/10.1126/science.307.5711.824.
Kastelein, J. J., Akdim, F., Stroes, E. S., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F., … Investigators, E. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine, 358(14), 1431–1443. https://doi.org/10.1056/nejmoa0800742.
Klopsteg, P. E. (1955). Role of government in basic research. Science, 121(3153), 781–784. https://doi.org/10.1126/science.121.3153.781.
Korn, D. (2000). Conflicts of interest in biomedical research. JAMA, 284(17), 2234–2237.
Kowalczyk, L. (2009, March 26). Ethics event spawns a tussle at Tufts: Speaker is out; now organizer is, too. Boston Globe.
Krieger, L. (2008, June 24). Stanford doctor’s stock raises ethics concerns. The Mercury News.
Lelyveld, J. (1963, November 29). Cigarette makers prosper despite debate on hazards. New York Times.
Lexchin, J. (2012). Those who have the gold make the evidence: How the pharmaceutical industry biases the outcomes of clinical trials of medications. Science and Engineering Ethics, 18(2), 247–261. https://doi.org/10.1007/s11948-011-9265-3.
Marshall, E. (2003). Conflict of interest. Zerhouni pledges review of NIH consulting in wake of allegations. Science, 302(5653), 2046. https://doi.org/10.1126/science.302.5653.2046.
Michael, D. (2008, May 1). Doubt is their product: How industry’s assault on science threatens your health (1st ed.). Oxford University Press. https://www.amazon.es/Doubt-Their-Product-Industrys-Threatens/dp/019530067X.
Nelson, B. (1968). Philip Handler: National Academy nominates a worldly “high priest”. Science, 162(3857), 981–984.
NIH to end funding for Moderate Alcohol and Cardiovascular Health trial (2018). NIH to end funding for Moderate Alcohol and Cardiovascular Health trial. https://www.nih.gov/news-events/news-releases/nih-end-funding-moderate-alcohol-cardiovascular-health-trial.
Oreskes, N. C. E. (2010). Merchants of doubt: How a handful of scientists obscured the truth on issues from tobacco smoke to global warming. Bloomsbury Press.
Parascandola, M. (2004). Skepticism, statistical methods, and the cigarette: A historical analysis of a methodological debate. Perspectives in Biology and Medicine, 47(2), 244–261.
Parascandola, M. (2007). A turning point for conflicts of interest: The controversy over the National Academy of Sciences’ first conflicts of interest disclosure policy. Journal of Clinical Oncology, 25(24), 3774–3779. https://doi.org/10.1200/JCO.2006.09.2890.
Parascandola, M., Weed, D. L., & Dasgupta, A. (2006). Two Surgeon General’s reports on smoking and cancer: A historical investigation of the practice of causal inference. Emerging Themes in Epidemiology, 3, 1. https://doi.org/10.1186/1742-7622-3-1.
Peterson, M. (2000, August 27). What’s black and white and sells medicine? New York Times.
Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth. (2004). Retrieved from Executive Summary. https://acnp.org/wp-content/uploads/2017/10/Task-Force-Report-on-SSRIs-and-Suicide-in-Youth-Exec-Summary.pdf.
Press, E. W. J. (2000). The kept university. Atlantic Monthly, 284, 2234–2237.
Proctor, R. S. L. (2008). Agnotology: The making and unmaking of ignorance. Stanford University Press.
Professors, A. A. o. U. (1915). Declaration of principles. Bulletin of the American Association of University Professors, 1(1).
Psaty, B. M., & Kronmal, R. A. (2008). Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA, 299(15), 1813–1817. https://doi.org/10.1001/jama.299.15.1813.
Rabin, R. (2018, March 17). Federal agency courted alcohol industry to fund study on benefits of moderate drinking. New York Times.
Reardon, S. (2015). NIH disclosure rules falter. Nature, 525(7569), 300–301. https://doi.org/10.1038/525300a.
Relman, A. S. (1984). Dealing with conflicts of interest. New England Journal of Medicine, 310(18), 1182–1183. https://doi.org/10.1056/NEJM198405033101809.
Relman, A. S. (1990). New “Information for Authors”—And readers. New England Journal of Medicine, 323(1), 56. https://doi.org/10.1056/NEJM199007053230111.
Rennie, D. (1997). Thyroid storm. JAMA, 277(15), 1238–1243.
Report From February 23, 2012, Pharmaceutical Compliance Roundtable. (2012). Retrieved from https://oig.hhs.gov/compliance/compliance-guidance/docs/pharmaceutical-compliance-roundtable.pdf.
Rochon, P. A., Gurwitz, J. H., Cheung, C. M., Hayes, J. A., & Chalmers, T. C. (1994). Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal. JAMA, 272(2), 108–113.
Rochon, P. A., Gurwitz, J. H., Simms, R. W., Fortin, P. R., Felson, D. T., Minaker, K. L., & Chalmers, T. C. (1994). A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 154(2), 157–163.
Ross, J. S., Hill, K. P., Egilman, D. S., & Krumholz, H. M. (2008). Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA, 299(15), 1800–1812. https://doi.org/10.1001/jama.299.15.1800.
Sass, J. (2008). Effective and practical disclosure policies: NRDC paper on workshop to identify key elements of disclosure policies for health science journals. Retrieved from Washington, DC. https://www.nrdc.org/sites/default/files/disclosure.pdf.
School, H. M. (2010). Changes to conflicts policy heighten transparency. Online.
Scientists in Government: Growing Concern Over Conflicts of Interest. (1960). Science, 131(3412), 1508–1509. https://doi.org/10.1126/science.131.3412.1508.
Seife, C. T. P. (2015, August 21). Why it’s OK for taxpayers to ‘snoop’ on scientists. Los Angeles Times.
Sibbald, B. (2001). Death but one unintended consequence of gene-therapy trial. CMAJ, 164(11), 1612.
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., … Geis, G. S. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, 284(10), 1247–1255.
Solomon, D. H., & Avorn, J. (2005). Coxibs, science, and the public trust. Archives of Internal Medicine, 165(2), 158–160. https://doi.org/10.1001/archinte.165.2.158.
Steinbrook, R. (2004). Financial conflicts of interest and the NIH. New England Journal of Medicine, 350(4), 327–330. https://doi.org/10.1056/NEJMp038247.
Steinman, M. A. (2001). Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. In M. A. Steinman, M. G. Shlipak & S. J. McPhee (Eds.), The American Journal of Medicine, 110(7), 551–557. https://www.ncbi.nlm.nih.gov/pubmed/11347622.
Steinman, M. A., Bero, L. A., Chren, M. M., & Landefeld, C. S. (2006). Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Annals of Internal Medicine, 145(4), 284–293.
Stelfox, H. T., Chua, G., O’Rourke, K., & Detsky, A. S. (1998). Conflict of interest in the debate over calcium-channel antagonists. New England Journal of Medicine, 338(2), 101–106. https://doi.org/10.1056/NEJM199801083380206.
Strom, S. (2016, December 27). National biotechnology panel faces new conflict of interest questions. New York Times.
Taylor, A. (2017, May 3). National academies revise conflict of interest policy. The Scientist.
Thacker, P. (2011). The ugly underbelly of medical research. Retrieved from http://pogoblog.typepad.com/pogo/2011/01/the-ugly-underbelly-of-medical-research.html.
Thacker, P. (2013). The slow pace of success in a ‘do something congress’. Retrieved from https://ethics.harvard.edu/blog/slow-pace-success-do-something-congress.
Thacker, P. (2014, December 2). Consumers deserve to know who’s funding health research. Harvard Business Review.
Thacker, P. (2015a). Database may uncover conflicts of interest for TV doctors. Columbia Journalism Review.
Thacker, P. (2015b, November 23). Where do science journalists draw the line? Columbia Journalism Review.
Thacker, P. (2016a, August 10). Don’t rewrite history: ‘Sunshine’ law was meant to protect docs from undue influence. STAT. Retrieved from https://www.statnews.com/2016/08/10/sunshine-act-revise-history/.
Thacker, P. (2016b). How a former reporter is helping big oil and gas frack the news: In the heated fight over fracking, industry gets insider tips on shaping its story. HuffPo. Retrieved from https://www.huffingtonpost.com/entry/colorado-fracking-free-press_us_57f565eae4b05f39c51e0916.
Thacker, P. (2016c, January 9). Scientists, give up your emails. New York Times.
Thacker, P. (2017a). Coca-Cola’s secret influence on medical and science journalists. BMJ, 357(j1638). https://doi.org/10.1136/bmj.j1638.
Thacker, P. (2017b, July 21). Flacking for GMOs: How the biotech industry cultivates positive media—And discourages criticism. The Progressive.
Thacker, P. (2017c, March 21). Why scientific transparency is so tricky. Pacific Standard.
Thacker, P. (2018, October 5). Time to act on industry influence over medicine and lay zombie arguments to rest. We have the evidence that change is needed, says Paul D Thacker. https://blogs.bmj.com/bmj/2018/10/05/paul-d-thacker-time-to-act-on-industry-influence-over-medicine-and-lay-zombie-arguments-to-rest/.
Therapy, A. S. o. G. (2000). Policy of the American Society of Gene Therapy on financial conflict of interest in clinical research. Milwaukee, WI.
Thompson, D. F. (1993). Understanding financial conflicts of interest. New England Journal of Medicine, 329(8), 573–576. https://doi.org/10.1056/NEJM199308193290812.
Thursby, J. G., & Thursby, M. C. (2003). Intellectual property. University licensing and the Bayh-Dole Act. Science, 301(5636), 1052. https://doi.org/10.1126/science.1087473.
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252–260. https://doi.org/10.1056/NEJMsa065779.
Twombly, R. (2007). Conflict-of-interest rules worry some scientists. Journal of the National Cancer Institute, 99(1), 6–9. https://doi.org/10.1093/jnci/djk037.
Tye, L. (1998). The father of spin: Edward L. Bernays & the birth of public relations (1st ed.). New York: Crown Publishers.
United States v Philip Morris et al., No. Civil Action No. 99–2496 (GK) (2004).
Vedantam, S. (2006, September 23). FDA told U.S. drug system is broken. Washington Post.
Wadman, M. (2009). Money in biomedicine: The senator’s sleuth. Nature, 461(7262), 330–334. https://doi.org/10.1038/461330a.
Weatherall, D. (2000). Academia and industry: Increasingly uneasy bedfellows. Lancet, 355(9215), 1574. https://doi.org/10.1016/S0140-6736(00)02211-X.
Weinfurt, K. P., Friedman, J. Y., Allsbrook, J. S., Dinan, M. A., Hall, M. A., & Sugarman, J. (2006). Views of potential research participants on financial conflicts of interest: Barriers and opportunities for effective disclosure. Journal of General Internal Medicine, 21(9), 901–906. https://doi.org/10.1111/j.1525-1497.2006.00502.x.
Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363(9418), 1341–1345. https://doi.org/10.1016/S0140-6736(04)16043-1.
Willman, D. (2003, December 7). Stealth merger: Drug companies and government research. Los Angeles Times. Retrieved from http://articles.latimes.com/2003/dec/07/nation/na-nih7.
Willman, D. (2005, February 2, 2005). NIH seeks ‘higher standard’. Los Angeles Times.
Wilson, M. (2016). The New England Journal of Medicine: Commercial conflict of interest and revisiting the Vioxx scandal. Indian Journal of Medical Ethics, 1(3), 167–171. https://doi.org/10.20529/IJME.2016.046.
Witt, M. D., & Gostin, L. O. (1994). Conflict of interest dilemmas in biomedical research. JAMA, 271(7), 547–551.
Wright, J. M., Perry, T. L., Bassett, K. L., & Chambers, G. K. (2001). Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA, 286(19), 2398–2400.
Zinner, D. E., Bolcic-Jankovic, D., Clarridge, B., Blumenthal, D., & Campbell, E. G. (2009). Participation of academic scientists in relationships with industry. Health Affairs (Millwood), 28(6), 1814–1825. https://doi.org/10.1377/hlthaff.28.6.1814.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Thacker, P.D. (2020). Transparency and Conflicts in Science: History of Influence, Scandal, and Denial. In: Çalıyurt, K. (eds) Integrity, Transparency and Corruption in Healthcare & Research on Health, Volume I. Accounting, Finance, Sustainability, Governance & Fraud: Theory and Application. Springer, Singapore. https://doi.org/10.1007/978-981-15-1424-1_1
Download citation
DOI: https://doi.org/10.1007/978-981-15-1424-1_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1423-4
Online ISBN: 978-981-15-1424-1
eBook Packages: Religion and PhilosophyPhilosophy and Religion (R0)